Evotec's Road Back Runs Through November 5

Evotec shares at EUR 2.81, down 49% this year, as H1 revenue falls 19.2% and adjusted EBITDA hits minus EUR 42.7 million.

Evotec has spent most of this year asking its shareholders for patience, and the market has been slow to grant it. The Hamburg-based drug discovery group is trying to rebuild momentum through fresh research alliances and a hard cost-cutting drive, but the stock tells its own story: at EUR 2.81, the shares have shed 49% since the start of the year.

The backdrop is a bruising twelve months marked by delayed milestone payments and fading operational traction. Management is attacking the problem from two directions at once — loading existing research platforms with new partners, and slimming down the cost base to nurse profitability back to health.

Fresh alliances in drug discovery

On the science side, Evotec continues to lean on collaborations with specialist players. An AI-driven partnership with Odyssey Therapeutics, focused on autoimmune and inflammatory diseases, was struck on August 6. A month later, on September 2, the company followed up with Plectonic Biotech, pairing its BiTCo platform with the partner's LOGIBODY technology to pursue T-cell-engaging approaches against solid tumors.

Its Just – Evotec Biologics unit also logged progress under a contract with the U.S. Department of Defense, advancing the antibody program JST-018 against orthopoxviruses into Phase I. Such project milestones underscore the scientific substance of the technology platforms, though they can only gradually relieve the near-term earnings pressure coming from the existing business.

Cost discipline through restructuring

The half-year figures lay bare the current strain. With the numbers confirmed roughly three weeks ago, first-half revenue totaled EUR 300.1 million, a decline of 19.2% year over year. Adjusted EBITDA for the same period came in at minus EUR 42.7 million.

Management reaffirmed its lowered full-year guidance about three weeks ago after milestones failed to materialize. On an investor conference, CFO Claire Hinshelwood pointed to a stabilization in business indicators and flagged future improvements in revenue.

The "Horizon" transformation program is the vehicle for a lasting earnings recovery, targeting total savings of EUR 75 million, with part of that relief expected to land in the current financial year.

What the market is watching

The next real test comes on November 5, 2026, when Evotec publishes its third-quarter results. Investors will comb the report for evidence that the stabilization signals from management hold up in the hard numbers.

The stock's near-term fate rests on a clearly defined level. As long as the 52-week low of EUR 2.76 touched yesterday holds, market participants see room for a technical base to form — a sign that recent bad news is already priced in. A sustained break below that mark, however, would risk a fresh loss of confidence and accelerate the downward move.

That is why the upcoming quarterly release carries so much weight. It is where the management's talk of improving economic indicators and stronger customer trust either survives contact with reality or doesn't. Until then, the shares remain a battleground between strategic hope and operational proof.

The central question for the valuation is how quickly the scientific collaborations can become commercially viable. New research projects raise the obvious follow-up: are partnerships like these enough to spark a fundamental turnaround? The technology itself is not in doubt. What remains open is how fast platform alliances translate into durable revenue — and whether a higher top line and technological demand can together lay the groundwork for a lasting recovery.

The counterweight is the long development cycles that come with early-stage work. The T-cell-engaging collaboration sits at a very early stage; years typically pass before preclinical concepts become approved treatments or meaningful milestone payments. In the meantime, such ventures tie up capital. Should customer demand stay hesitant despite management's upbeat comments, earnings could fall short of expectations. The recent guidance cut showed how sensitive the market is to operational setbacks, and without visible near-term cash inflows, the risk remains that research progress simply evaporates.